Characterizing Antibody Cross-reactivity for Immunoaffinity Purification of Analytes Prior to Multiplexed Liquid Chromatography-tandem Mass Spectrometry
Overview
Authors
Affiliations
Background: Immunoassays for 1α,25-dihydroxyvitamin D [1α,25(OH)(2)D] lack analytical specificity. We characterized the cross-reactivity of an anti-1α,25(OH)(2)D antibody with purified vitamin D metabolites and used these data to map the chemical features of 1α,25(OH)(2)D that are important for antibody binding. Additionally, we hypothesized that when combined with isotope-dilution liquid chromatography-tandem mass spectrometry (LC-MS/MS), antibody cross-reactivity could be used to semiselectively enrich for structurally similar metabolites of vitamin D in a multiplexed assay.
Methods: Sample preparation consisted of immunoaffinity enrichment with a solid-phase anti-1α,25(OH)(2)D antibody and derivatization. Analytes were quantified with LC-MS/MS. Supplementation and recovery studies were performed for 11 vitamin D metabolites. We developed a method for simultaneously quantifying 25(OH)D(2), 25(OH)D(3), 24,25(OH)(2)D(3), 1α,25(OH)(2)D(2), and 1α,25(OH)(2)D(3) that included deuterated internal standards for each analyte.
Results: The important chemical features of vitamin D metabolites for binding to the antibody were (a) native orientation of the hydroxyl group on carbon C3 in the A ring, (b) the lack of substitution at carbon C4 in the A ring, and (c) the overall polarity of the vitamin D metabolite. The multiplexed method had lower limits of quantification (20% CV) of 0.2 ng/mL, 1.0 ng/mL, 0.06 ng/mL, 3.4 pg/mL, and 2.8 pg/mL for 25(OH)D(2), 25(OH)D(3), 24,25(OH)(2)D(3), 1α,25(OH)(2)D(2), and 1α,25(OH)(2)D(3), respectively. Method comparisons to 3 other LC-MS/MS methods yielded an r(2) value >0.9, an intercept less than the lower limit of quantification, and a slope statistically indistinguishable from 1.0.
Conclusions: LC-MS/MS can be used to characterize antibody cross-reactivity, a conclusion supported by our multiplexed assay for 5 vitamin D metabolites with immunoenrichment in a targeted metabolomic assay.
Oral Sodium Bicarbonate and Bone Turnover in CKD: A Secondary Analysis of the BASE Pilot Trial.
Raphael K, Katz R, Larive B, Kendrick C, Isakova T, Sprague S J Am Soc Nephrol. 2024; 35(1):57-65.
PMID: 38170601 PMC: 10786609. DOI: 10.1681/ASN.0000000000000264.
Wise S, Hahm G, Burdette C, Tai S, Camara J, Sempos C J Steroid Biochem Mol Biol. 2023; 231:106318.
PMID: 37169270 PMC: 10330830. DOI: 10.1016/j.jsbmb.2023.106318.
Hsu S, Criqui M, Ginsberg C, Hoofnagle A, Ix J, McClelland R JBMR Plus. 2022; 6(12):e10697.
PMID: 36530185 PMC: 9751658. DOI: 10.1002/jbm4.10697.
Best C, Thummel K, Hsu S, Lin Y, Zelnick L, Kestenbaum B J Steroid Biochem Mol Biol. 2022; 226:106206.
PMID: 36404469 PMC: 11536320. DOI: 10.1016/j.jsbmb.2022.106206.
Williams A, Zhao S, Brock G, Kline D, Echouffo-Tcheugui J, Effoe V BMJ Open Diabetes Res Care. 2022; 10(5).
PMID: 36162866 PMC: 9516211. DOI: 10.1136/bmjdrc-2022-002931.